Beyond monoamines-novel targets for treatment-resistant depression: A comprehensive review

Current Neuropharmacology

Volumn 13, Issue 5, 2015, Pages 636-655

  Rosenblat, Joshua D ^a   McIntyre, Roger S ^a,b   Alves, Gilberto S ^c   Fountoulakis, Konstantinos N ^d   Carvalho, André F ^c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Brain derived neurotrophic factor (BDNF); Cytokines; Glutamate; Infliximab; Insulin; Ketamine; Pioglitazone; Riluzole; Treatment resistant depression

Indexed keywords

BASIMGLURANT; BIPERIDEN; BRAIN DERIVED NEUROTROPHIC FACTOR; BUPRENORPHINE; CYCLOSERINE; GLUTAMIC ACID; INFLIXIMAB; INSULIN; KETAMINE; MECAMYLAMINE; METYRAPONE; NEUROTROPHIN; PIOGLITAZONE; RAPASTINEL; RILUZOLE; SCOPOLAMINE; TUMOR NECROSIS FACTOR ALPHA; VARENICLINE; ANTIDEPRESSANT AGENT; BIOGENIC AMINE;

ARTICLE; BIOENERGY; CHOLINERGIC SYSTEM; CYTOKINE PRODUCTION; EVIDENCE BASED PRACTICE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; INFORMATION PROCESSING; METABOLIC DISORDER; MITOCHONDRIAL DYNAMICS; NITROSATIVE STRESS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; HUMAN; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOGENIC MONOAMINES; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; HUMANS;

EID: 84946728731     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159x13666150630175044     Document Type: Article

References (173)

1. Kessler, R.C.; Akiskal, H.S.; Ames, M.; Birnbaum, H.; Greenberg, P.; Hirschfeld, R.M.; Jin, R.; Merikangas, K.R.; Simon, G.E.; Wang, P.S. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am. J. Psychiatry, 2006, 163(9), 1561-1568. http://dx.doi.org/10.1176/appi.ajp.163.9.1561
2. WHO, Depression Fact Sheet. http://www.who.int/mediacentre/factsheets/fs369/en/. Updated 2012, accessed August 2014
3. Gaynes, B.N.; Warden, D.; Trivedi, M.H.; Wisniewski, S.R.; Fava, M.; Rush, A.J. What did STAR*D teach us? Results from a largescale, practical, clinical trial for patients with depression. Psychiatric Serv. (Washington, D.C.) 2009, 60(11), 1439-1445. http://dx.doi.org/10.1176/ps.2009.60.11.1439
4. McIntyre, R.S.; Filteau, M.J.; Martin, L.; Patry, S.; Carvalho, A.; Cha, D.S.; Barakat, M.; Miguelez, M. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J. Affect. Disord., 2014, 156, 1-7. http://dx.doi.org/10.1016/j.jad.2013.10.043
5. Carvalho, A.F.; Berk, M.; Hyphantis, T.N.; McIntyre, R.S. The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother. Psychosom., 2014, 83(2), 70-88. http://dx.doi.org/10.1159/000357500
6. Lopez-Munoz, F.; Alamo, C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr. Pharm. Des., 2009, 15(14), 1563-1586. http://dx.doi.org/10.2174/138161209788168001
7. Rizvi, S.J.; Grima, E.; Tan, M.; Rotzinger, S.; Lin, P.; McIntyre, R. S.; Kennedy, S. H. Treatment-resistant depression in primary care across Canada. Can. J. Psychiatry, 2014, 59(7), 349-357.
8. Thomas, L.; Kessler, D.; Campbell, J.; Morrison, J.; Peters, T. J.; Williams, C.; Lewis, G.; Wiles, N. Prevalence of treatmentresistant depression in primary care: cross-sectional data. Br.J. Gen. Pract., 2013, 63(617), e852-858. http://dx.doi.org/10.3399/bjgp13X675430
9. Rosenblat, J.D.; Cha, D.S.; Mansur, R.B.; McIntyre, R.S. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog. Neuro-psychopharmacol. Boil. Psychiatry, 2014, 53, 23-34.
10. Soczynska, J.K.; Mansur, R.B.; Brietzke, E.; Swardfager, W.; Kennedy, S.H.; Woldeyohannes, H.O.; Powell, A.M.; Manierka, M.S.; McIntyre, R.S. Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav. Brain Res., 2012, 235(2), 302-317. http://dx.doi.org/10.1016/j.bbr.2012.07.026
11. McIntyre, R.S.; Powell, A.M.; Kaidanovich-Beilin, O.; Soczynska, J.K.; Alsuwaidan, M.; Woldeyohannes, H.O.; Kim, A.S.; Gallaugher, L.A. The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders. Behav. Brain Res., 2013, 237, 164-171. http://dx.doi.org/10.1016/j.bbr.2012.09. 021
12. Hashimoto, K., The role of glutamate on the action of antidepressants. Prog. Neuro-Psychopharmacol. Boil. Psychiatry, 2011, 35(7), 1558-1568.
13. Hashimoto, K., Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res. Rev., 2009, 61(2), 105-123. http://dx.doi.org/10.1016/j.brainresrev.2009.05.005
14. Machado-Vieira, R.; Manji, H.K.; Zarate, C.A. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist, 2009, 15(5), 525-539.
15. Machado-Vieira, R.; Zarate, C.A., Jr. Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments. Depress. Anxiety, 2011, 28(4), 267-281. http://dx.doi.org/10.1002/da.20800
16. Leonard, B.E. Impact of inflammation on neurotransmitter changes in major depression: an insight into the action of antidepressants. Prog. Neuro-psychopharmacol. Boil. Psychiatry, 2014, 48, 261-267.
17. Lee, S. Y.; Lee, S. J.; Han, C.; Patkar, A. A.; Masand, P. S.; Pae, C. U. Oxidative/nitrosative stress and antidepressants: targets for novel antidepressants. Prog. Neuro-Psychopharmacol. Boil. Psychiatry, 2013, 46, 224-235.
18. Boyce, P.; Hopwood, M. Manipulating melatonin in managing mood. Acta Psychiatry. Scand. Suppl., 2013, (444), 16-23.
19. Lanfumey, L.; Mongeau, R.; Hamon, M. Biological rhythms and melatonin in mood disorders and their treatments. Pharmacol. Ther., 2013, 138(2), 176-184. http://dx.doi.org/10.1016/j.pharmthera.2013.01.005
20. Raju, T.N. The Nobel chronicles. 1927: Julius Wagner-Jauregg (1857-1940). Lancet, 1998, 352(9141), 1714. http://dx.doi.org/10.1016/S0140-6736(05)61500-0
21. Brydon, L.; Walker, C.; Wawrzyniak, A.; Whitehead, D.; Okamura, H.; Yajima, J.; Tsuda, A.; Steptoe, A. Synergistic effects of psychological and immune stressors on inflammatory cytokine and sickness responses in humans. Brain Behav. Immun., 2009, 23(2), 217-224. http://dx.doi.org/10.1016/j.bbi.2008.09.007
22. Walker, J.R.; Graff, L.A.; Dutz, J.P.; Bernstein, C.N. Psychiatric disorders in patients with immune-mediated inflammatory diseases: prevalence, association with disease activity, and overall patient well-being. J. Rheumatol. Suppl., 2011, 88, 31-35. http://dx.doi.org/10.3899/jrheum.110900
23. Steptoe, A.; Hamer, M.; Chida, Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and me ta-analysis. Brain Behav. Immun., 2007, 21(7), 901-912. http://dx.doi.org/10.1016/j.bbi.2007.03.011
24. McNamara, R.K.; Lotrich, F.E. Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target? Expert Rev. Neurother., 2012, 12(9), 1143-1161. http://dx.doi.org/10.1586/ern. 12.98
25. Reichenberg, A.; Yirmiya, R.; Schuld, A.; Kraus, T.; Haack, M.; Morag, A.; Pollmacher, T. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psychiatry, 2001, 58(5), 445-452. http://dx.doi.org/10.1001/archpsyc.58.5.445
26. Wright, C.E.; Strike, P.C.; Brydon, L.; Steptoe, A. Acute inflammation and negative mood: mediation by cytokine activation. Brain Behave. Immun., 2005, 19(4), 345-350. http://dx.doi.org/10.1016/j.bbi.2004.10.003
27. Raison, C.L.; Broadwell, S.D.; Borisov, A.S.; Manatunga, A.K.; Capuron, L.; Woolwine, B.J.; Jacobson, I.M.; Nemeroff, C.B.; Miller, A.H. Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C. Brain Behav. Immun., 2005, 19(1), 23-27. http://dx.doi.org/10.1016/j.bbi.2004.05.001
28. Dunn, A.J.; Swiergiel, A.H.; de Beaurepaire, R. Cytokines as mediators of depression: what can we learn from animal studies? Neurosci. Biobehav. Rev., 2005, 29(4 5), 891-909. http://dx.doi.org/10.1016/j.neubiorev.2005.03.023
29. Carvalho, L.A.; Torre, J.P.; Papadopoulos, A.S.; Poon, L.; Juruena, M.F.; Markopoulou, K.; Cleare, A.J.; Pariante, C.M. Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. J. Affect. Disord., 2013, 148(1), 136-140. http://dx.doi.org/10.1016/j.jad.2012.10.036
30. Capuron, L.; Neurauter, G.; Musselman, D.L.; Lawson, D.H.; Nemeroff, C.B.; Fuchs, D.; Miller, A.H. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol. Psychiatry, 2003, 54(9), 906-914. http://dx.doi.org/10.1016/S0006-3223(03)00173-2
31. Capuron, L.; Ravaud, A.; Neveu, P.J.; Miller, A.H.; Maes, M.; Dantzer, R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol. Psychiatry, 2002, 7(5), 468-473. http://dx.doi.org/10.1038/sj.mp.4000995
32. Harry, G.J.; Kraft, A.D. Microglia in the developing brain: a potential target with lifetime effects. Neurotoxicology, 2012, 33(2), 191-206. http://dx.doi.org/10.1016/j.neuro.2012.01.012
33. Ekdahl, C.T. Microglial activation tuning and pruning adult neurogenesis. Front. Pharmacol, 2012, 3, 41. http://dx.doi.org/10.3389/fphar.2012.00041
34. Lifschytz, T.; Segman, R.; Shalom, G.; Lerer, B.; Gur, E.; Golzer, T.; Newman, M.E., Basic mechanisms of augmentation of antidepressant effects with thyroid hormone. Curr. Drug Targets, 2006, 7(2), 203-210. http://dx.doi.org/10.2174/138945006775515482
35. Miller, A.H.; Haroon, E.; Raison, C.L.; Felger, J.C. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress. Anxiety, 2013, 30(4), 297-306. http://dx.doi.org/10.1002/da.22084
36. Raison, C.L.; Miller, A.H. Malaise, melancholia and madness: the evolutionary legacy of an inflammatory bias. Brain Behav. Immun., 2013, 31, 1-8. http://dx.doi.org/10.1016/j.bbi.2013.04.009
37. Stertz, L.; Magalhaes, P.V.; Kapczinski, F. Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Curr. Opin. Psychiatry, 2013, 26(1), 19-26. http://dx.doi.org/10.1097/YCO.0b013e32835aa4b4
38. Hashimoto, K.; Malchow, B.; Falkai, P.; Schmitt, A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur. Arch. Psychiatry Clin. Neurosci., 2013, 263(5), 367-377. http://dx.doi.org/10.1007/s00406-013-0399-y
39. Sigalas, P.D.; Garg, H.; Watson, S.; McAllister-Williams, R.H.; Ferrier, I. N. Metyrapone in treatment-resistant depression. Ther. Adv. Psychopharmacol., 2012, 2(4), 139-149. http://dx.doi.org/10.1177/2045125312436597
40. Cowen, P.J. Not fade away: the HPA axis and depression. Psychol. Med., 2010, 40(1), 1-4. http://dx.doi.org/10.1017/S0033291709005558
41. Raison, C.L.; Rutherford, R.E.; Woolwine, B.J.; Shuo, C.; Schettler, P.; Drake, D.F.; Haroon, E.; Miller, A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry (Chicago, Ill.), 2013, 70(1), 31-41. http://dx.doi.org/10.1001/2013.jamapsychiatry.4
42. Ramiro, S.; Gaujoux-Viala, C.; Nam, J.L.; Smolen, J.S.; Buch, M.; Gossec, L.; van der Heijde, D.; Winthrop, K.; Landewe, R. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann. Rheum. Dis., 2014, 73(3), 529-535. http://dx.doi.org/10.1136/annrheumdis-2013-204575
43. Vane, J.R.; Botting, R.M. The mechanism of action of aspirin. Thromb. Res., 2003, 110(5 6), 255-258. http://dx.doi.org/10.1016/S0049-3848(03)00379-7
44. Berk, M.; Dean, O.; Drexhage, H.; McNeil, J.J.; Moylan, S.; O'Neil, A.; Davey, C.G.; Sanna, L.; Maes, M. Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med., 2013, 11, 74. http://dx.doi.org/10.1186/1741-7015-11-74
45. Goldstein, B.I.; Kemp, D.E.; Soczynska, J.K.; McIntyre, R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J. Clin. Psychiatry, 2009, 70(8), 1078-1090. http://dx.doi.org/10.4088/JCP.08r04505
46. Muller, N. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr. Opin. Investig. Drugs, 2010, 11(1), 31-42.
47. Abbasi, S.H.; Hosseini, F.; Modabbernia, A.; Ashrafi, M.; Akhondzadeh, S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J. Affect. Disord., 2012, 141(2 3), 308-314. http://dx.doi.org/10.1016/j.jad.2012.03.033
48. Faridhosseini, F.; Sadeghi, R.; Farid, L.; Pourgholami, M. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum. Psychopharmacol., 2014, 29(3), 216-223. http://dx.doi.org/10.1002/hup.2401
49. Na, K.S.; Lee, K.J.; Lee, J.S.; Cho, Y.S.; Jung, H.Y. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis. Prog. Neuro-Psychopharmacol. Boil. Psychiatry, 2014, 48, 79-85.
50. Green, G.A. Understanding NSAIDs: from aspirin to COX-2. Clin. Cornerstone, 2001, 3(5), 50-60. http://dx.doi.org/10.1016/S1098-3597(01)90069-9
51. Simopoulos, A.P. Omega-3 fatty acids in health and disease and in growth and development. Am. J. Clin. Nutr., 1991, 54(3), 438-463.
52. Calder, P.C. The relationship between the fatty acid composition of immune cells and their function. Prostaglandins Leukot. Essent. Fatty Acids, 2008, 79(3 5), 101-108. http://dx.doi.org/10.1016/j. plefa.2008.09.016
53. Gertsik, L.; Poland, R.E.; Bresee, C.; Rapaport, M.H. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J. Clin. Psychopharmacol., 2012, 32(1), 61-4. http://dx.doi.org/10.1097/JCP.0b013e31823f3b5f
54. Jazayeri, S.; Tehrani-Doost, M.; Keshavarz, S.A.; Hosseini, M.; Djazayery, A.; Amini, H.; Jalali, M.; Peet, M. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust. N Z. J. Psychiatry, 2008, 42(3), 192-198. http://dx.doi.org/10.1080/00048670701827275
55. Peet, M.; Horrobin, D.F. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen. Psychiatry, 2002, 59(10), 913-919. http://dx.doi.org/10.1001/archpsyc.59.10.913
56. Lopresti, A.L.; Hood, S.D.; Drummond, P.D. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immunemodulating and neuroprotective effects. J. Psychopharmacol., (Oxford, England) 2012, 26(12), 1512-1524.
57. Bergman, J.; Miodownik, C.; Bersudsky, Y.; Sokolik, S.; Lerner, P. P.; Kreinin, A.; Polakiewicz, J.; Lerner, V. Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebocontrolled, pilot clinical study. Clin. Neuropharmacol., 2013, 36(3), 73-77. http://dx.doi.org/10.1097/WNF.0b013e31828ef969
58. Sanmukhani, J.; Satodia, V.; Trivedi, J.; Patel, T.; Tiwari, D.; Panchal, B.; Goel, A.; Tripathi, C.B. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother. Res.,2014, 28(4), 579-585. http://dx.doi.org/10.1002/ptr.5025
59. Lopresti, A.L.; Maes, M.; Maker, G.L.; Hood, S.D.; Drummond, P.D. Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. J. Affect. Disord., 2014, 167, 368-375. http://dx.doi.org/10.1016/j.jad.2014.06.001
60. Levine, J.; Cholestoy, A.; Zimmerman, J. Possible antidepressant effect of minocycline. Am. J. Psychiatry, 1996, 153(4), 582. http://dx.doi.org/10.1176/ajp.153.4.582b
61. Savitz, J.; Preskorn, S.; Teague, T.K.; Drevets, D.; Yates, W.; Drevets, W. Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, doubleblind, placebo-controlled, 2x2 clinical trial. BMJ Open., 2012, 2(1), e000643. http://dx.doi.org/10.1136/bmjopen-2011-000643
62. Mello, B.S.; Monte, A.S.; McIntyre, R.S.; Soczynska, J.K.; Custodio, C.S.; Cordeiro, R.C.; Chaves, J.H.; Vasconcelos, S.M.; Nobre, H.V., Jr.; Florenco de Sousa, F.C.; Hyphantis, T.N.; Carvalho, A.F.; Macedo, D.S. Effects of doxycycline on depressive-like behavior in mice after lipopolysaccharide (LPS) administration. J. Psychiat. Res., 2013, 47(10), 1521-1529. http://dx.doi.org/10.1016/j.jpsychires.2013.06.008
63. Rawdin, B.J.; Mellon, S.H.; Dhabhar, F.S.; Epel, E.S.; Puterman, E.; Su, Y.; Burke, H.M.; Reus, V.I.; Rosser, R.; Hamilton, S.P.; Nelson, J.C.; Wolkowitz, O.M. Dysregulated relationship of inflammation and oxidative stress in major depression. Brain Behav. Immune., 2013, 31, 143-152. http://dx.doi.org/10.1016/j.bbi.2012.11.011
64. Gill, R.; Tsung, A.; Billiar, T. Linking oxidative stress to inflammation: Toll-like receptors. Free Radic. Boil. Med., 2010, 48(9), 1121-1132. http://dx.doi.org/10.1016/j.freeradbiomed.2010.01.006
65. Anderson, G.; Berk, M.; Dean, O.; Moylan, S.; Maes, M. Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications. CNS Drugs, 2014, 28(1), 1-10. http://dx.doi.org/10.1007/s40263-013-0119-1
66. Pompella, A.; Visvikis, A.; Paolicchi, A.; De Tata, V.; Casini, A. F. The changing faces of glutathione, a cellular protagonist. Biochem. Pharmacol., 2003, 66 (8), 1499-1503. http://dx.doi.org/10.1016/S0006-2952(03)00504-5
67. Aboul-Fotouh, S. Coenzyme Q10 displays antidepressant-like activity with reduction of hippocampal oxidative/nitrosative DNA damage in chronically stressed rats. Pharmacol. Biochem. Behav., 2013, 104, 105-112. http://dx.doi.org/10.1016/j.pbb.2012.12.027
68. Morris, G.; Anderson, G.; Berk, M.; Maes, M. Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications. Mo. Neurobiol., 2013, 48 (3), 883-903. http://dx.doi.org/10.1007/s12035-013-8477-8
69. Acuna-Castroviejo, D.; Martin, M.; Macias, M.; Escames, G.; Leon, J.; Khaldy, H.; Reiter, R.J. Melatonin, mitochondria, and cellular bioenergetics. J. Pineal Res., 2001, 30(2), 65-74. http://dx.doi.org/10.1034/j.1600-079X.2001.300201.x
70. Rich, P.R., The molecular machinery of Keilin's respiratory chain. Biochem. Soc. Trans., 2003, 31(Pt 6), 1095-1105. http://dx.doi.org/10.1042/bst0311095
71. Belanger, M.; Allaman, I.; Magistretti, P.J. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab., 2011, 14(6), 724-738. http://dx.doi.org/10.1016/j.cmet.2011.08.016
72. Moylan, S.; Berk, M.; Dean, O.M.; Samuni, Y.; Williams, L.J.; O'Neil, A.; Hayley, A.C.; Pasco, J.A.; Anderson, G.; Jacka, F.N.; Maes, M. Oxidative and nitrosative stress in depression: why so much stress? Neurosci. Biobehav. Rev., 2014, 45, 46-62. http://dx.doi.org/10.1016/j.neubiorev.2014.05.007
73. Moylan, S.; Maes, M.; Wray, N.R.; Berk, M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol. Psychiatry, 2013, 18(5), 595-606. http://dx.doi.org/10.1038/mp.2012.33
74. Zhou, L.; Zhu, D.Y. Neuronal nitric oxide synthase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide, 2009, 20(4), 223-230.
75. Eu, J.P.; Liu, L.; Zeng, M.; Stamler, J.S. An apoptotic model for nitrosative stress. Biochemistry, 2000, 39(5), 1040-1047. http://dx.doi.org/10.1021/bi992046e
76. Palta, P.; Samuel, L.J.; Miller, E.R., 3rd; Szanton, S.L. Depression and oxidative stress: results from a meta-analysis of observational studies. Psychosom. Med., 2014, 76(1), 12-19. http://dx.doi.org/10.1097/PSY.0000000000000009
77. Berk, M.; Malhi, G.S.; Gray, L.J.; Dean, O.M. The promise of Nacetylcysteine in neuropsychiatry. Trends Pharmacol. Sci., 2013, 34(3), 167-177. http://dx.doi.org/10.1016/j.tips.2013.01.001
78. Das, P.; Tanious, M.; Fritz, K.; Dodd, S.; Dean, O.M.; Berk, M.; Malhi, G.S., Metabolite profiles in the anterior cingulate cortex of depressed patients differentiate those taking N-acetyl-cysteine versus placebo. Austr. NZ. J. Psychiatry, 2013, 47(4), 347-354. http://dx.doi.org/10.1177/0004867412474074
79. Berk, M.; Dean, O.M.; Cotton, S.M.; Jeavons, S.; Tanious, M.; Kohlmann, K.; Hewitt, K.; Moss, K.; Allwang, C.; Schapkaitz, I.; Robbins, J.; Cobb, H.; Ng, F.; Dodd, S.; Bush, A.I.; Malhi, G.S. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J. Clin. Psychiatry, 2014, 75(6), 628-636. http://dx.doi.org/10.4088/JCP.13m08454
80. Miller, G.E.; Chen, E.; Zhou, E.S. If it goes up, must it come down? Chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans. Psychol. Bull., 2007, 133(1), 25-45. http://dx.doi.org/10.1037/0033-2909.133.1.25
81. McAllister-Williams, R.H.; Ferrier, I.N.; Young, A.H. Mood and neuropsychological function in depression: the role of corticosteroids and serotonin. Psychol. Med., 1998, 28(3), 573-584. http://dx.doi.org/10.1017/S0033291798006680
82. Murphy, B.E., Steroids and depression. J. Steroid Biochem. Mol. Boil., 1991, 38(5), 537-559. http://dx.doi.org/10.1016/0960-0760(91)90312-S
83. Sanacora, G.; Treccani, G.; Popoli, M., Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology, 2012, 62(1), 63-77. http://dx.doi.org/10.1016/j.neuropharm.2011.07.036
84. Jahn, H.; Schick, M.; Kiefer, F.; Kellner, M.; Yassouridis, A.; Wiedemann, K. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch. Gen. Psychiatry, 2004, 61(12), 1235-1244. http://dx.doi.org/10.1001/archpsyc.61.12.1235
85. Cardoso, C.; Kingdon, D.; Ellenbogen, M.A. A meta-analytic review of the impact of intranasal oxytocin administration on cortisol concentrations during laboratory tasks: Moderation by method and mental health. Psychoneuroendocrinology, 2014, 49C, 161-170. http://dx.doi.org/10.1016/j.psyneuen.2014.07.014
86. Keating, C.; Dawood, T.; Barton, D.A.; Lambert, G.W.; Tilbrook, A.J. Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder. BMC Psychiatry, 2013, 13, 124. http://dx.doi.org/10.1186/1471-244X-13-124
87. Miller, A.H.; Maletic, V.; Raison, C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry, 2009, 65 (9), 732-741. http://dx.doi.org/10.1016/j.biopsych.2008.11.029
88. Vancampfort, D.; Correll, C.U.; Wampers, M.; Sienaert, P.; Mitchell, A.J.; De Herdt, A.; Probst, M.; Scheewe, T.W.; De Hert, M. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. Psychol. Med., 2013, 1-12.
89. Kozumplik, O.; Uzun, S. Metabolic syndrome in patients with depressive disorder--features of comorbidity. Psychiatria Danubina 2011, 23(1), 84-88.
90. Kan, C.; Silva, N.; Golden, S.H.; Rajala, U.; Timonen, M.; Stahl, D.; Ismail, K. A systematic review and meta-analysis of the association between depression and insulin resistance. Diabetes Care, 2013, 36(2), 480-489. http://dx.doi.org/10.2337/dc12-1442
91. McNay, E.C.; Recknagel, A.K. Brain insulin signaling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiol. Learn. Memory, 2011, 96(3), 432-442. http://dx.doi.org/10.1016/j.nlm. 2011.08.005
92. Karunakaran, U.; Park, K.G. A systematic review of oxidative stress and safety of antioxidants in diabetes: focus on islets and their defense. Diab. Metabol. J., 2013, 37(2), 106-112. http://dx.doi.org/10.4093/dmj.2013.37.2.106
93. Katon, W.; von Korff, M.; Ciechanowski, P.; Russo, J.; Lin, E.; Simon, G.; Ludman, E.; Walker, E.; Bush, T.; Young, B. Behavioral and clinical factors associated with depression among individuals with diabetes. Diabetes Care, 2004, 27(4), 914-920. http://dx.doi.org/10.2337/diacare.27.4.914
94. Mansur, R.B.; Cha, D.S.; Woldeyohannes, H.O.; Soczynska, J.K.; Zugman, A.; Brietzke, E.; McIntyre, R.S. Diabetes Mellitus and Disturbances in Brain Connectivity: A Bidirectional Relationship? Neuromol. Med., 2014, 16, 658-68. http://dx.doi.org/10.1007/s12017-014-8316-8
95. Rotte, M.; Baerecke, C.; Pottag, G.; Klose, S.; Kanneberg, E.; Heinze, H.J.; Lehnert, H. Insulin affects the neuronal response in the medial temporal lobe in humans. Neuroendocrinology, 2005, 81(1), 49-55. http://dx.doi.org/10.1159/000084874
96. Strachan, M.W. Insulin and cognitive function in humans: experimental data and therapeutic considerations. Biochem. Soc. Trans., 2005, 33(Pt 5), 1037-1040. http://dx.doi.org/10.1042/BST0331037
97. Benedict, C.; Hallschmid, M.; Schultes, B.; Born, J.; Kern, W. Intranasal insulin to improve memory function in humans. Neuroendocrinology, 2007, 86(2), 136-142. http://dx.doi.org/10.1159/000106378
98. Benedict, L.; Nelson, C.A.; Schunk, E.; Sullwold, K.; Seaquist, E.R. Effect of insulin on the brain activity obtained during visual and memory tasks in healthy human subjects. Neuroendocrinology, 2006, 83(1), 20-26. http://dx.doi.org/10.1159/000093338
99. Shemesh, E.; Rudich, A.; Harman-Boehm, I.; Cukierman-Yaffe, T. Effect of intranasal insulin on cognitive function: a systematic review. J. Clin. Endocrinol. Metabol., 2012, 97(2), 366-376. http://dx.doi.org/10.1210/jc.2011-1802
100. McIntyre, R.S.; Soczynska, J.K.; Woldeyohannes, H.O.; Lewis, G.F.; Leiter, L.A.; MacQueen, G.M.; Miranda, A.; Fulgosi, D.; Konarski, J.Z.; Kennedy, S.H. Thiazolidinediones: novel treatments for cognitive deficits in mood disorders? Expert Opin. Pharmacother., 2007, 8(11), 1615-1628. http://dx.doi.org/10.1517/14656566.8.11.1615
101. Salehi-Sadaghiani, M.; Javadi-Paydar, M.; Gharedaghi, M.H.; Zandieh, A.; Heydarpour, P.; Yousefzadeh-Fard, Y.; Dehpour, A. R. NMDA receptor involvement in antidepressant-like effect of pioglitazone in the forced swimming test in mice. Psychopharmacology (Berl), 2012, 223(3), 345-355. http://dx.doi.org/10.1007/s00213-012-2722-0
102. Gold, P.W.; Licinio, J.; Pavlatou, M.G. Pathological parainflammation and endoplasmic reticulum stress in depression: potential translational targets through the CNS insulin, klotho and PPAR-gamma systems. Mol. Psychiatry, 2013, 18(2), 154-165. http://dx.doi.org/10.1038/mp.2012.167
103. Medzhitov, R. Origin and physiological roles of inflammation. Nature, 2008, 454(7203), 428-435. http://dx.doi.org/10.1038/nature07201
104. Hotamisligil, G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell, 2010, 140(6), 900-917. http://dx.doi.org/10.1016/j.cell.2010.02.034
105. Kemp, D.E.; Ismail-Beigi, F.; Ganocy, S.J.; Conroy, C.; Gao, K.; Obral, S.; Fein, E.; Findling, R.L.; Calabrese, J.R. Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. J. Affect. Dis., 2012, 136(3), 1164-1173. http://dx.doi.org/10.1016/j.jad.2011.06.033
106. Sepanjnia, K.; Modabbernia, A.; Ashrafi, M.; Modabbernia, M.J.; Akhondzadeh, S. Pioglitazone adjunctive therapy for moderate-tosevere major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology, 2012, 37(9), 2093-2100. http://dx.doi.org/10.1038/npp.2012.58
107. Kashani, L.; Omidvar, T.; Farazmand, B.; Modabbernia, A.; Ramzanzadeh, F.; Tehraninejad, E.S.; Ashrafi, M.; Tabrizi, M.; Akhondzadeh, S. Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology, 2013, 38(6), 767-776. http://dx.doi.org/10.1016/j.psyneuen.2012. 08.010
108. Kemp, D.E.; Ismail-Beigi, F.; Calabrese, J.R. Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome. Am. J. Psychiatry, 2009, 166(5), 619. http://dx.doi.org/10.1176/appi.ajp.2008.08081195
109. de Sousa, R.T.; Machado-Vieira, R.; Zarate, C.A., Jr.; Manji, H.K. Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder. Expert Opin. Ther. Targets, 2014, 18(10), 1131-1147. http://dx.doi.org/10.1517/14728222.2014. 940893
110. Allen, P.J. Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value? Neurosci. Biobehav. Rev., 2012, 36(5), 1442-1462. http://dx.doi.org/10.1016/j.neubiorev.2012.03.005
111. Iosifescu, D.V.; Bolo, N.R.; Nierenberg, A.A.; Jensen, J.E.; Fava, M.; Renshaw, P.F. Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biol. Psychiatry, 2008, 63(12), 1127-1134. http://dx.doi.org/10.1016/j.biopsych.2007.11.020
112. Nierenberg, A.A.; Kansky, C.; Brennan, B.P.; Shelton, R.C.; Perlis, R.; Iosifescu, D.V. Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development. Aus. N. Z. J. Psychiatry, 2013, 47(1), 26-42. http://dx.doi.org/10.1177/0004867412449303
113. Roitman, S.; Green, T.; Osher, Y.; Karni, N.; Levine, J. Creatine monohydrate in resistant depression: a preliminary study. Bipolar Dis., 2007, 9(7), 754-758. http://dx.doi.org/10.1111/j.1399-5618.2007.00532.x
114. Kondo, D.G.; Sung, Y.H.; Hellem, T.L.; Fiedler, K.K.; Shi, X.; Jeong, E.K.; Renshaw, P.F. Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study. J. Affect. Disord., 2011, 135(1 3), 354-361. http://dx.doi.org/10.1016/j.jad.2011.07.010
115. Papakostas, G.I.; Alpert, J.E.; Fava, M. S-adenosyl-methionine in depression: a comprehensive review of the literature. Curr. Psychiatry Rep., 2003, 5(6), 460-466. http://dx.doi.org/10.1007/s11920-003-0085-2
116. Papakostas, G.I.; Cassiello, C.F.; Iovieno, N. Folates and Sadenosylmethionine for major depressive disorder. Can. J. Psychiatry, 2012, 57(7), 406-413.
117. Papakostas, G.I.; Fava, M.; Thase, M.E. Treatment of SSRIresistant depression: a meta-analysis comparing within-versus across-class switches. Biol. Psychiatry, 2008, 63(7), 699-704. http://dx.doi.org/10.1016/j.biopsych.2007.08.010
118. Alpert, J.E.; Papakostas, G.; Mischoulon, D.; Worthington, J.J., 3rd; Petersen, T.; Mahal, Y.; Burns, A.; Bottiglieri, T.; Nierenberg, A.A.; Fava, M. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J. Clin. Psychopharmacol., 2004, 24(6), 661-664. http://dx.doi.org/10.1097/01.jcp.0000145339.45794.cd
119. Papakostas, G.I.; Mischoulon, D.; Shyu, I.; Alpert, J.E.; Fava, M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am. J. Psychiatry, 2010, 167(8), 942-948. http://dx.doi.org/10.1176/appi. ajp.2009.09081198
120. Papakostas, G.I.; Shelton, R.C.; Zajecka, J.M.; Etemad, B.; Rickels, K.; Clain, A.; Baer, L.; Dalton, E.D.; Sacco, G.R.; Schoenfeld, D.; Pencina, M.; Meisner, A.; Bottiglieri, T.; Nelson, E.; Mischoulon, D.; Alpert, J.E.; Barbee, J.G.; Zisook, S.; Fava, M. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am. J. Psychiatry, 2012, 169(12), 1267-1274. http://dx.doi.org/10.1176/appi.ajp.2012.11071114
121. Farah, A. The role of L-methylfolate in depressive disorders. CNS Spectr., 2009, 14(1 Suppl 2), 2-7.
122. Miller, A.L. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Alter. Med. Rev. J. Clin. Ther., 2008, 13(3), 216-226.
123. Owen, R.T. Folate augmentation of antidepressant response. Drugs Today, 2013, 49(12), 791-798. http://dx.doi.org/10.1358/dot.2013. 49.12.2086138
124. Fava, M.; Mischoulon, D. Folate in depression: efficacy, safety, differences in formulations, and clinical issues. J. Clin. Psychiatry, 2009, 70 Suppl 5, 12-17. http://dx.doi.org/10.4088/JCP.8157su1c.03
125. Reichardt, L.F. Neurotrophin-regulated signalling pathways. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 2006, 361(1473), 1545-1564. http://dx.doi.org/10.1098/rstb.2006.1894
126. Duman, R.S.; Aghajanian, G.K. Synaptic dysfunction in depression: potential therapeutic targets. Science, 2012, 338(6103), 68-72. http://dx.doi.org/10.1126/science.1222939
127. Ota, K.T.; Duman, R.S. Environmental and pharmacological modulations of cellular plasticity: role in the pathophysiology and treatment of depression. Neurobiol. Dis., 2013, 57, 28-37. http://dx.doi.org/10.1016/j.nbd.2012.05.022
128. Duman, R S.; Li, N. A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 2012, 367(1601), 2475-2484.
129. Ogunshola, O.O.; Bogdanova, A.Y. Epo and non-hematopoietic cells: what do we know? Methods Mol. Boil., 2013, 982, 13-41. http://dx.doi.org/10.1007/978-1-62703-308-4_2
130. Miskowiak, K.W.; Vinberg, M.; Harmer, C.J.; Ehrenreich, H.; Kessing, L.V. Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology (Berl), 2012, 219(3), 687-698. http://dx.doi.org/10.1007/s00213-011-2511-1
131. Miskowiak, K.W.; Vinberg, M.; Christensen, E.M.; Bukh, J.D.; Harmer, C.J.; Ehrenreich, H.; Kessing, L.V. Recombinant human erythropoietin for treating treatment-resistant depression: a doubleblind, randomized, placebo-controlled phase 2 trial. Neuropsychopharmacoloy, 2014, 39(6), 1399-1408. http://dx.doi.org/10.1038/npp.2013.335
132. Abelaira, H.M.; Reus, G.Z.; Neotti, M.V.; Quevedo, J. The role of mTOR in depression and antidepressant responses. Life Sci., 2014, 101(1 2), 10-14. http://dx.doi.org/10.1016/j.lfs.2014.02.014
133. Niciu, M.J.; Henter, I.D.; Luckenbaugh, D.A.; Zarate, C.A., Jr.; Charney, D.S. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu. Vew Pharmacol. Toxicol., 2014, 54, 119-139. http://dx.doi.org/10.1146/annurev-pharmtox-011613-135950
134. Browne, C.A.; Lucki, I. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front. Pharmacol., 2013, 4, 161. http://dx.doi.org/10.3389/fphar.2013.00161
135. McGirr, A.; Berlim, M.T.; Bond, D.J.; Fleck, M.P.; Yatham, L.N.; Lam, R.W. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol. Med., 2014, 1-12.
136. Zarate, C.A., Jr.; Singh, J.B.; Carlson, P.J.; Brutsche, N.E.; Ameli, R.; Luckenbaugh, D.A.; Charney, D.S.; Manji, H.K. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry, 2006, 63(8), 856-864. http://dx.doi.org/10.1001/archpsyc.63.8.856
137. Murrough, J.W.; Iosifescu, D.V.; Chang, L.C.; Al Jurdi, R.K.; Green, C.E.; Perez, A.M.; Iqbal, S.; Pillemer, S.; Foulkes, A.; Shah, A.; Charney, D.S.; Mathew, S.J. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am. J. Psychiatry, 2013, 170(10), 1134-1142. http://dx.doi.org/10.1176/appi.ajp.2013.13030392
138. Torjesen, I. Ketamine helps a third of patients with treatment resistant depression, finds small UK study. BMJ, 2014, 348, g2576. http://dx.doi.org/10.1136/bmj.g2576
139. Murrough, J.W.; Perez, A.M.; Pillemer, S.; Stern, J.; Parides, M.K.; aan het Rot, M.; Collins, K.A.; Mathew, S.J.; Charney, D.S.; Iosifescu, D.V., Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol. Psychiatry, 2013, 74(4), 250-256. http://dx.doi.org/10.1016/j.biopsych.2012.06.022
140. Diamond, P.R.; Farmery, A.D.; Atkinson, S.; Haldar, J.; Williams, N.; Cowen, P.J.; Geddes, J.R.; McShane, R. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J. Psychopharmacol. (Oxford England), 2014, 28(6), 536-544. http://dx.doi.org/10.1177/0269881114527361
141. Price, R.B.; Iosifescu, D.V.; Murrough, J.W.; Chang, L.C.; Al Jurdi, R.K.; Iqbal, S.Z.; Soleimani, L.; Charney, D.S.; Foulkes, A.L.; Mathew, S.J. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatmentresistant depression. Depress. Anxiety, 2014, 31(4), 335-343. http://dx.doi.org/10.1002/da.22253
142. Ballard, E.D.; Ionescu, D.F.; Vande Voort, J.L.; Niciu, M.J.; Richards, E.M.; Luckenbaugh, D.A.; Brutsche, N.E.; Ameli, R.; Furey, M.L.; Zarate, C.A., Jr. Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety. J. Psychiat. Res., 2014, 58, 161-166. http://dx.doi.org/10.1016/j.jpsychires.2014.07.027
143. Lapidus, K.A.; Levitch, C.F.; Perez, A. M.; Brallier, J.W.; Parides, M.K.; Soleimani, L.; Feder, A.; Iosifescu, D.V.; Charney, D.S.; Murrough, J.W. A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder. Biol. Psychiatry, 2014, 76, 970-6. http://dx.doi.org/10.1016/j.biopsych.2014.03.026
144. Owen, R.T. Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole. Drugs Today, 2012, 48(7), 469-478.
145. Zarate, C.A., Jr.; Payne, J.L.; Quiroz, J.; Sporn, J.; Denicoff, K.K.; Luckenbaugh, D.; Charney, D.S.; Manji, H. K. An open-label trial of riluzole in patients with treatment-resistant major depression. Am. J. Psychiatry, 2004, 161(1), 171-174. http://dx.doi.org/10.1176/appi.ajp.161.1.171
146. Sanacora, G.; Kendell, S.F.; Levin, Y.; Simen, A.A.; Fenton, L.R.; Coric, V.; Krystal, J.H. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol. Psychiatry, 2007, 61(6), 822-825. http://dx.doi.org/10.1016/j.biopsych.2006.08.037
147. Preskorn, S.H.; Baker, B.; Kolluri, S.; Menniti, F.S.; Krams, M.; Landen, J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101, 606, in patients with treatmentrefractory major depressive disorder. J. Clin. Psychopharmacol., 2008, 28(6), 631-637. http://dx.doi.org/10.1097/JCP.0b013e31818 a6cea
148. Moghaddam, B.; Adams, B.; Verma, A.; Daly, D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci.,1997, 17(8), 2921-2927.
149. Nations, K.R.; Bursi, R.; Dogterom, P.; Ereshefsky, L.; Gertsik, L.; Mant, T.; Schipper, J. Maximum tolerated dose evaluation of the AMPA modulator Org 26576 in healthy volunteers and depressed patients: a summary and method analysis of bridging research in support of phase II dose selection. Drugs R. D., 2012, 12(3), 127-139. http://dx.doi.org/10.2165/11634360-000000000-00000
150. Tokita, K.; Yamaji, T.; Hashimoto, K. Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacol. Biochem. Behav., 2012, 100 (4), 688-704. http://dx.doi.org/10.1016/j.pbb.2011.04.016
151. Bauer, M.; Adli, M.; Bschor, T.; Pilhatsch, M.; Pfennig, A.; Sasse, J.; Schmid, R.; Lewitzka, U. Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. Neuropsychobiology, 2010, 62(1), 36-42. http://dx.doi.org/10.1159/000314308
152. Du, J.; Gray, N.A.; Falke, C.A.; Chen, W.; Yuan, P.; Szabo, S.T.; Einat, H.; Manji, H.K. Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J. Neurosci., 2004, 24(29), 6578-6589. http://dx.doi.org/10.1523/JNEUROSCI.1258-04.2004
153. Nonaka, S.; Chuang, D.M. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport, 1998, 9(9), 2081-4. http://dx.doi.org/10.1097/00001756-199806220-00031
154. Hashimoto, R.; Hough, C.; Nakazawa, T.; Yamamoto, T.; Chuang, D. M. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J. Neurochem., 2002, 80(4), 589-597. http://dx.doi.org/10.1046/j.0022-3042.2001.00728.x
155. Berrocoso, E.; Sanchez-Blazquez, P.; Garzon, J.; Mico, J.A. Opiates as antidepressants. Curr. Pharm. Des., 2009, 15(14), 1612-1622. http://dx.doi.org/10.2174/138161209788168100
156. Tenore, P. L. Psychotherapeutic benefits of opioid agonist therapy. J. Addict. Dis., 2008, 27(3), 49-65. http://dx.doi.org/10.1080/10550880802122646
157. Lutz, P. E.; Kieffer, B. L. Opioid receptors: distinct roles in mood disorders. Trends Neurosci., 2013, 36(3), 195-206. http://dx.doi.org/10.1016/j.tins.2012.11.002
158. Torregrossa, M.M.; Isgor, C.; Folk, J.E.; Rice, K.C.; Watson, S.J.; Woods, J.H. The delta-opioid receptor agonist (+)BW373U86 regulates BDNF mRNA expression in rats. Neuropsychopharmacology, 2004, 29(4), 649-659. http://dx.doi.org/10.1038/sj.npp.1300345
159. Zhang, H.; Shi, Y.G.; Woods, J.H.; Watson, S.J.; Ko, M.C. Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies. Eur. J. Pharmacol., 2007, 570(1 3), 89-96. http://dx.doi.org/10.1016/j.ejphar.2007.05.045
160. Gerra, G.; Borella, F.; Zaimovic, A.; Moi, G.; Bussandri, M.; Bubici, C.; Bertacca, S. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend., 2004, 75(1), 37-45. http://dx.doi.org/10.1016/j.drugalcdep.2003.11.017
161. Bodkin, J.A.; Zornberg, G.L.; Lukas, S.E.; Cole, J.O. Buprenorphine treatment of refractory depression. J. Clin. Psychopharmacol., 1995, 15(1), 49-57. http://dx.doi.org/10.1097/00004714-199502000-00008
162. Janowsky, D.S.; el-Yousef, M.K.; Davis, J.M.; Sekerke, H.J. A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972, 2(7778), 632-635. http://dx.doi.org/10.1016/S0140-6736(72) 93021-8
163. Dilsaver, S.C. Pharmacologic induction of cholinergic system upregulation and supersensitivity in affective disorders research. J. Clin. Psychopharmacol., 1986, 6(2), 65-74. http://dx.doi.org/10.1097/00004714-198604000-00002
164. Kasper, S.; Moises, H.W.; Beckmann, H. The anticholinergic biperiden in depressive disorders. Pharmacopsychiatria, 1981, 14(6), 195-198. http://dx.doi.org/10.1055/s-2007-1019597
165. Drevets, W.C.; Zarate, C.A., Jr.; Furey, M.L. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol. Psychiatry, 2013, 73(12), 1156-1163. http://dx.doi.org/10.1016/j.biopsych.2012.09.031
166. Rami, A.; Krieglstein, J. Muscarinic-receptor antagonist scopolamine rescues hippocampal neurons from death induced by glutamate. Brain Res., 1998, 788(1 2), 323-326. http://dx.doi.org/10.1016/S0006-8993(98)00041-9
167. Furey, M.L.; Drevets, W.C. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebocontrolled clinical trial. Arch. Gen. Psychiatry, 2006, 63(10), 1121-1129. http://dx.doi.org/10.1001/archpsyc.63.10.1121
168. Drevets, W.C.; Furey, M.L. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol. Psychiatry, 2010, 67(5), 432-8. http://dx.doi.org/10.1016/j.biopsych.2009.11.021
169. Khajavi, D.; Farokhnia, M.; Modabbernia, A.; Ashrafi, M.; Abbasi, S.H.; Tabrizi, M.; Akhondzadeh, S. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled Study. J. Clin. Psychiatry, 2012, 73(11), 1428-1433. http://dx.doi.org/10.4088/JCP.12m07706
170. Philip, N.S.; Carpenter, L.L.; Tyrka, A.R.; Price, L.H. Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature. Psychopharmacology, (Berl) 2010, 212(1), 1-12.
171. George, T.P.; Sacco, K.A.; Vessicchio, J.C.; Weinberger, A.H.; Shytle, R.D. Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study. J. Clin. Psychopharmacol., 2008, 28(3), 340-344. http://dx.doi.org/10.1097/JCP.0b013e318172b49e
172. Philip, N.S.; Carpenter, L.L.; Tyrka, A.R.; Whiteley, L.B.; Price, L.H. Varenicline augmentation in depressed smokers: an 8-week, open-label study. J. Clin. Psychiatry, 2009, 70(7), 1026-1031. http://dx.doi.org/10.4088/JCP.08m04441
173. Zarate, C.A., Jr.; Mathews, D.; Ibrahim, L.; Chaves, J.F.; Marquardt, C.; Ukoh, I.; Jolkovsky, L.; Brutsche, N.E.; Smith, M.A.; Luckenbaugh, D.A. A randomized trial of a low-trapping nonselective N-methyl-d-aspartate channel blocker in major depression. Biol. Psychiatry, 2013, 74(4), 257-264. http://dx.doi.org/10.1016/j.biopsych.2012.10.019